GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CARsgen Therapeutics Holdings Ltd (HKSE:02171) » Definitions » ROIC %

CARsgen Therapeutics Holdings (HKSE:02171) ROIC % : -130.80% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is CARsgen Therapeutics Holdings ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. CARsgen Therapeutics Holdings's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2023 was -130.80%.

As of today (2024-05-31), CARsgen Therapeutics Holdings's WACC % is 10.38%. CARsgen Therapeutics Holdings's ROIC % is -128.05% (calculated using TTM income statement data). CARsgen Therapeutics Holdings earns returns that do not match up to its cost of capital. It will destroy value as it grows.


CARsgen Therapeutics Holdings ROIC % Historical Data

The historical data trend for CARsgen Therapeutics Holdings's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CARsgen Therapeutics Holdings ROIC % Chart

CARsgen Therapeutics Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROIC %
-19.19 -48.54 -114.91 -117.65 -140.48

CARsgen Therapeutics Holdings Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROIC % Get a 7-Day Free Trial Premium Member Only -111.84 -96.43 -121.47 -114.79 -130.80

Competitive Comparison of CARsgen Therapeutics Holdings's ROIC %

For the Biotechnology subindustry, CARsgen Therapeutics Holdings's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CARsgen Therapeutics Holdings's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CARsgen Therapeutics Holdings's ROIC % distribution charts can be found below:

* The bar in red indicates where CARsgen Therapeutics Holdings's ROIC % falls into.



CARsgen Therapeutics Holdings ROIC % Calculation

CARsgen Therapeutics Holdings's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROIC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-858.263 * ( 1 - -0.05% )/( (639.058 + 583.463)/ 2 )
=-858.6921315/611.2605
=-140.48 %

where

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3085.281 - 68.029 - ( 2532.749 - max(0, 190.963 - 2569.157+2532.749))
=639.058

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2468.893 - 51.304 - ( 2023.22 - max(0, 214.618 - 2048.744+2023.22))
=583.463

CARsgen Therapeutics Holdings's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2023 is calculated as:

ROIC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-896.722 * ( 1 - -0.12% )/( (789.322 + 583.463)/ 2 )
=-897.7980664/686.3925
=-130.80 %

where

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2893.003 - 48.159 - ( 2377.888 - max(0, 365.112 - 2420.634+2377.888))
=789.322

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2468.893 - 51.304 - ( 2023.22 - max(0, 214.618 - 2048.744+2023.22))
=583.463

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CARsgen Therapeutics Holdings  (HKSE:02171) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, CARsgen Therapeutics Holdings's WACC % is 10.38%. CARsgen Therapeutics Holdings's ROIC % is -128.05% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


CARsgen Therapeutics Holdings ROIC % Related Terms

Thank you for viewing the detailed overview of CARsgen Therapeutics Holdings's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


CARsgen Therapeutics Holdings (HKSE:02171) Business Description

Traded in Other Exchanges
Address
No. 388 Yindu Road, Building 12, CMC Preparation Center, Xuhui District, Shanghai, CHN
CARsgen Therapeutics Holdings Ltd is a global clinical-stage biopharmaceutical company discovering, researching and developing cell therapies in the People's Republic of China and the United States of America.
Executives
Guo Bingsen 2401 A concert party to an agreement to buy shares
Guo Huaqing 2101 Beneficial owner
Li Zonghai 2401 A concert party to an agreement to buy shares
Wang Huamao 2401 A concert party to an agreement to buy shares
Gic (ventures) Pte. Ltd. 2201 Interest of corporation controlled by you
Gic Private Limited 2201 Interest of corporation controlled by you
Gic Special Investments Private Limited 2102 Investment manager
Yang Zhi 2201 Interest of corporation controlled by you
Prowell Ventures Pte Ltd 2201 Interest of corporation controlled by you
Bvcf Realization Fund, L.p. 2201 Interest of corporation controlled by you
Bvcf Realization Fund Gp, Ltd. 2201 Interest of corporation controlled by you
Zhejiang Jolly Healthcare Investment Management Limited 2201 Interest of corporation controlled by you
Applied Biomaterial Ltd. 2201 Interest of corporation controlled by you
Zhejiang Jolly Pharmaceutical Co., Ltd. 2201 Interest of corporation controlled by you
Zhejiang Zuoli Innovation Medical Investment Management Co., Ltd. 2101 Beneficial owner

CARsgen Therapeutics Holdings (HKSE:02171) Headlines

No Headlines